QuidelOrtho (QDEL) to Report Q4 and Full Year 2025 Financial Results on February 11, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: PRnewswire
- Earnings Release Schedule: QuidelOrtho will announce its Q4 and full-year 2025 financial results after market close on February 11, 2026, providing investors with crucial performance data and future outlook.
- Conference Call Timing: Following the earnings release, QuidelOrtho will hold a conference call at 2:00 PM PT (5:00 PM ET) to discuss financial results in detail and address investor inquiries.
- Participation Method: Investors can access the conference call via the 'Investor Relations' section of the company's website or by dialing 833-470-1428 (domestic) and +1 929-526-1599 (international), ensuring broad investor participation.
- Replay Availability: A replay of the earnings call will be available shortly after the event on the company's 'Investor Relations' page, allowing those unable to attend live to access the information.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like QDEL with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on QDEL
Wall Street analysts forecast QDEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 26.50 USD with a low forecast of 22.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 26.790
Low
22.00
Averages
26.50
High
31.00
Current: 26.790
Low
22.00
Averages
26.50
High
31.00
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QuidelOrtho Releases Podcast Episode on Blood Supply Challenges
- Blood Supply Pressures: Michelle Mullens from QuidelOrtho highlights in the podcast that the modern blood supply faces pressures from climate change and persistent demand, emphasizing the importance of stable donations for healthcare safety.
- Donor Engagement: Mullens stresses that consistent donor engagement is crucial for maintaining continuity in healthcare, particularly in today's complex clinical practice environment.
- Ecosystem Connectivity: The podcast explores the interconnectedness of donors, diagnostics, and patient care, revealing how effective communication and engagement can enhance the stability of the blood supply chain.
- Diagnostic Solutions: QuidelOrtho is dedicated to providing fast, accurate, and reliable diagnostic solutions to improve patient outcomes, showcasing the company's expertise and innovation in the field of blood testing.
Continue Reading
QuidelOrtho Releases Podcast Episode on Blood Supply Challenges
- Blood Supply Pressure: Climate change and routine trauma events create unpredictable demand for blood products, forcing healthcare institutions to face greater challenges in blood supply chain management, which impacts patient treatment outcomes.
- Rising Demand for O-Type Blood: The growth of low-titer whole blood programs accelerates the consumption of O-type units, necessitating more targeted donor recruitment and precise inventory management to meet the increasing clinical needs.
- Automation Enhances Resilience: Standardized, high-throughput immunohematology platforms improve safety and ensure operational continuity during surges, allowing staff to focus on complex cases, thereby enhancing overall healthcare service quality.
- Importance of Donors: Every blood type plays a crucial role in supporting direct transfusion needs and the diagnostic reagents necessary for safe transfusions, emphasizing the importance of consistent year-round donations to maintain safety across the healthcare system.
Continue Reading